Delving into the Latest Updates on Shanghai Kangjing Bioscience Co. Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Immune System Diseases

Hemic and Lymphatic Diseases

Antibody fusion proteins

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	1
Immune System Diseases	1
Hemic and Lymphatic Diseases	1
Nervous System Diseases	1

Top 5 Drug Type	Count

Antibody fusion proteins	1

Top 5 Target	Count

C3 x C3b	1

Part 1（健康人剂量递增阶段）主要研究目的：评估健康人接受 CG001 注射后的安全性和耐受性；次要研究目的：评估健康人接受 CG001 注射后的药代动力学（PK）特征；评估健康人接受 CG001 注射后的免疫原性；探索性目的：探索健康人接受 CG001 注射后的药效/免疫学标志物。 Part 2（PNH患者剂量递增阶段）主要研究目的：评估 PNH 患者接受 CG001 注射后的安全性和耐受性；次要研究目的：评估 PNH 患者接受 CG001 注射后的 PK 特征；评估 PNH 患者接受 CG001 注射后的免疫原性；初步评估 PNH 患者接受 CG001 注射后的有效性；探索性目的：探索PNH患者接受CG001注射后的药效/免疫学标志物。

[Translation]

Part 1 (healthy subjects dose escalation phase) Main study objectives: evaluate the safety and tolerability of CG001 after injection in healthy subjects; Secondary study objectives: evaluate the pharmacokinetic (PK) characteristics of CG001 after injection in healthy subjects; evaluate the immunogenicity of CG001 after injection in healthy subjects; Exploratory objectives: explore the pharmacodynamic/immunological markers of CG001 after injection in healthy subjects. Part 2 (PNH patients dose escalation phase) Main study objectives: evaluate the safety and tolerability of CG001 after injection in PNH patients; Secondary study objectives: evaluate the PK characteristics of CG001 after injection in PNH patients; evaluate the immunogenicity of CG001 after injection in PNH patients; preliminarily evaluate the effectiveness of CG001 after injection in PNH patients; Exploratory objectives: explore the pharmacodynamic/immunological markers of CG001 after injection in PNH patients.

Start Date11 Apr 2022

Sponsor / Collaborator

Shanghai Kangjing Bioscience Co. Ltd.

100 Clinical Results associated with Shanghai Kangjing Bioscience Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Kangjing Bioscience Co. Ltd.

Login to view more data

100 Deals associated with Shanghai Kangjing Bioscience Co. Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Kangjing Bioscience Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 12 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data